Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control

Area of Science:

• Oncology
• Radiotherapy
• Molecular Biology

Background:

• Cyclooxygenase-2 (COX-2) is implicated in various cancers.
• The role of COX-2 in cervical cancer treated with radiotherapy requires further elucidation.

Purpose of the Study:

• To investigate the correlation between cyclooxygenase-2 (COX-2) expression levels and clinical outcomes in cervical cancer patients undergoing radiotherapy.
• To assess the prognostic significance of COX-2 in relation to local control, cause-specific survival, and patterns of failure.

Main Methods:

• Tumor biopsies from cervical cancer patients were analyzed for COX-2 expression using immunohistochemistry.
• Clinical data including stage, grade, tumor size, hemoglobin levels, and radiotherapy dose were collected.
• Kaplan-Meier method and log-rank tests were employed to evaluate survival rates and prognostic factors.

Main Results:

• COX-2 distribution staining emerged as a significant prognostic factor for both local control and cause-specific survival.
• Patients with high COX-2 expression exhibited significantly lower 5-year cause-specific survival (22%) and pelvic control (42%) compared to those with low COX-2 expression (90% and 92%, respectively).
• COX-2 staining intensity positively correlated with tumor size (p = 0.02).

Conclusions:

• Increased COX-2 expression is associated with reduced pelvic control and cause-specific survival in cervical cancer patients treated with radiotherapy.
• These findings suggest that COX-2 may be a viable therapeutic target in cervical cancer treatment.
• The potential of COX-2 inhibitors to enhance radiotherapy efficacy warrants further investigation.